Showing posts with label therapeutics. Show all posts
Showing posts with label therapeutics. Show all posts

Monday, April 11, 2016

Record Attendance Expected! Don't Miss IBC's 18th Annual TIDES


Register by Friday, April 15th and save $300! To save, use the code B16180BLOG100



Experts Provide Key Success Factors for Drug Development and Manufacturing:

Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors
Richard DiMarchi, Ph.D. Standiford H. Cox Professor of Chemistry, Indiana University

Drisapersen: Case Study
Robert Baffi, Ph.D. Executive VP, Technical Operations, BioMarin Pharmaceuticals

Quark's Long History of Oligonucleotide Development
Danny Zurr, Ph.D. Chairman and CEO, Quark Pharmaceuticals Inc. 

Technologies for Targeting Molecules to Sites of Diseases
John Reed MD, Ph.D Global Head of Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.


TIDES 2016 is on pace for record attendance with 800+ global attendees expected to attend this year’s meeting, held May 9-12, 2016 in Long Beach, California – will you be there?

Register your team today and access the science, technologies and contracts you need to accelerate your oligonucleotide and peptide products through the clinic towards commercial success.

Your registration grants you access to:
  • 800+ attendees representing 25 countries help you forge new business and scientific collaborations
  • 100+ speaker presentations across 5 tracks provide a customized agenda of solutions for your company’s current challenges
  • 70+ exhibitors demonstrate the latest products and technologies to accelerate your therapeutic to market
  • 40+ poster presentations keep you abreast of cutting-edge industry and academic research

Plus, be sure to register this week to gain access to Attendee Connect powered by partneringONE, the digital networking platform that allows you to view the full attendee list, pre-schedule meetings, and send private messages to attendees before, during and after the event.



Share this article with your social network, just click below to share now!


Tuesday, April 5, 2016

Exclusive Interview with Dr. Bruce Riser, CEO, BLR-Bio, LLC



IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Bruce L. Riser, Ph.D., CEO, BLR-Bio, LLC for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

What are the biggest challenges of bringing new agents with novel targets to the market?

BR: There are really two big challenges when bringing new agents with novel targets to the market. First, many investors and potential partners are not familiar with the target, or they do not have the comfort that exists with an established target. Second, there can be misperceptions in the scientific community and in the biopharmaceutical industry where an agent is associated with another type of development creating a negative halo. On the first challenge, it is easy to see a proven target and to line up, jumping on the bandwagon with others trying to either win the race to launch first or to attempt to find a niche in an already established area. The problem of course is that lining up with everyone else does not provide the opportunity to develop and launch a true breakthrough therapy that can change the treatment paradigms and have a breakthrough impact on peoples' lives. Instead, investors and companies that line up for the established target often find they are trailing others to the market and are never able to successfully establish themselves in the market. It really takes a visionary to see the potential of a new target and have the insight and strength to invest in it. The second challenge, dealing with miss-associations of a novel therapy with other developments can be truly vexing. Our peptides target the novel CCN signaling pathway, leveraging the unique qualities of CCN3 to target the control of ECM changes in response to injury, blocking fibrosis and creating an environment for re-establishment of complete tissue homeostasis. By creating peptide libraries and conducting diverse in vitro and in vivo screens we have identified specific regions with the CCN3 protein responsible for blocking single, or multiple, pathways to fibroblast and cancer growth, and fibrosis formation. Unlike other products such as antibodies directed against the pro-fibrotic CCN2, that appear to partially block a single pathway, our novel therapy regulates vs. simply blocking, thus allowing reestablishment of the body's healthy equilibrium.

With several peptide products in the pipeline in preclinical development and a wide range of possible disease applications, how have you selected your lead indication target(s)?

BR: Having several products covering a wide variety of diseases is great and choosing lead indications to pursue is a wonderful challenge to have. In reality, the two lead indications that we have chosen to pursue have as much to do with the research that we have done with my team as it does the extreme health care need. My long background in academia, clinical nephrology/public health, and pharmaceutical drug R&D has driven the way we do drug discovery at BLR Bio. First, working to clearly understand the pathways to disease before selecting a target, and trying not to get caught up by targets in vogue. Then, testing our peptides in multiple related diseases before moving into the clinic. Our pipeline was created out of our long-term interest in fibrosis and the extracellular matrix in biology and disease, particularly in renal fibrosis as a complication of diabetes an area of great medical need. This has led to the selection of diabetic nephropathy as a main target for one of our lead products. Since our target, and the peptide inhibitor of our target, are involved in many other forms of fibrosis and other disease involving the miss-regulation of matricellular signaling, this creates other exciting therapeutic indications down the road. These include NASH, IPF, MD, and scleroderma to name a few.

I began my career in cancer research, and we know now that the extracellular matrix and matricellular signaling proteins such as the CCNs are critical also in the formation and resolution of tumors. The pro-fibrotic CCNs, CCN2 and CCN4 in particular have been shown to be important for the establishment and likely invasion and metastases in numerous tumors. The opportunity to use CCN3-based therapy to, not only halt the cancer, but also to target the microenvironment is an exciting one. Our company is particularly excited about the potential in pancreatic cancer. We have an established relationship with thought leaders in the cancer field and are moving forward with development work, partnering with some of these world experts. To add to the excitement of the therapies, our company also is developing a diagnostic/theranostic based on the same technology platform. It holds the promise of either stand-alone or companion diagnostics for development.

What are the key advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

BR: As you know, peptide-based drugs are one of the most rapidly growing areas in therapeutic development. More than 100 peptide-based drugs are on the market with several effective in cancer treatment. There is good reason for this. In size, falling between small molecule drugs and "biologics", they have many of the benefits of both while shedding many of the deficiencies. For example, because of their small size they gain many delivery benefits over biologics. First, better penetration of tissue at the site of action. This is crucial in fibrotic disease and cancer where there is a very strong barrier to penetration. Second, it allows for many more delivery options, including oral formulation. The earlier assumption of poor metabolic stability of peptides has just not proven to be the case. Although there is often rapid clearance from circulation, the previous assumptions about required PK by classic definition has also proven to be not relevant, since a specific and sustained biological activity at the target receptor is characteristic of many peptides. Unlike small molecules they are based on sequences that have evolved to react with specific receptors and often at very low concentrations. This results in very low off target effects. Last, since they can be chemically synthesized the ease and cost to manufacture are more nearly like that of small molecules. The majority of approved peptides are in the 15 amino acids (aa) range or smaller, and they treat a broad range of diseases.

How do you see academia and industry collaborating in the future to advance promising peptide therapeutics into commercially viable products?

BR: First, we think that academia will play a significant role in the creation of new peptide-based therapies in the future. Since the last decade has seen a decline in the number of newly approved drugs from large pharma, and recently there has been a strong trend for these same companies to dramatically reduce their discovery effort, this creates a large opportunity for novel peptide therapies and academic-initiated translational research. This does not necessarily mean that the new paradigm will be that large strategic companies will license early stage assets directly from Universities. Rather, we anticipate that the most promising discoveries will lead to the creation of start-up companies and the building of defendable IP. Then, large pharmaceuticals will court these start-ups as they progress to become true biotechnology companies with completion of phase I, phase II clinical trials or beyond. We think that the best of these emerging biotech companies will then expand their ability to do discovery and early stage development. They will also be able to clearly evaluate and in-license additional opportunities in academia. These are exactly the skills now lacking in big pharma. These successful discovery biotech's will become the future pipelines for drugs that will go to the mid and large pharma companies centered on late development and marketing. I envision BLR Bio as becoming one of these discovery companies able to contribute significantly to filling this gap.

Want to hear more from Dr. Riser? Join him this May in Long Beach, CA for the 18th annual TIDES - Save $300 when you register using the code B16180BLOG100. Click here to register. 



Share this article with your social network, just click below to share now!


Tuesday, March 29, 2016

The Current Value of the Global Peptide Therapeutics Market



"The number of companies specializing in the manufacture of therapeutic peptides has been shrinking over the last 15 years with fewer new companies entering the market than those leaving it."  

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA. 


In this interview, Dr. Lax discusses:
  • - The current estimated value of the global peptide therapeutics market.
  • - The key factors that contribute to the constant growth of the global peptide therapeutics market.
  • - The advantages/disadvantages to a consolidated peptide manufacturing industry.
  • - Which emerging markets are leading the forefront of peptide therapeutics research and development
  • - Opportunities that are emerging due to recent advancements in manufacturing and delivery technology

 Access the complete interview here.

PLUS! As a blog reader, you are eligible to save $300 when registering for TIDES. Use the code B16180BLOG100 to activate your savings. Click here to register.


Share this article with your social network, just click below to share now!


Friday, March 25, 2016

Analytical Controls in an Evolving Technology and Regulatory Landscape


 
IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rachel Orr, Senior Scientist, GlaxoSmithKline R&D, United Kingdom for an exclusive interview that delves into analytical controls in an evolving technology and regulatory landscape, the topic of her presentation at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.


1. What key analytical challenges do oligonucleotide developers need to overcome in order to achieve regulatory approval?

Oligonucleotides are inherently difficult to analyze - they are neither traditional, small nor large molecules, and the techniques and well established methodologies for pharmaceutical analysis are all focused on these distinct classes. In addition, there is very limited regulatory guidance when it comes to oligonucleotides, so there are no set rules to follow. There are often discussions as to whether oligonucleotide analysis should follow small molecule rules and regulations or align with biopharmaceuticals; opinions are divided.

With limited experience across the industry in marketing applications it is difficult to assess what is needed in order to gain regulatory approval and this is one of the biggest challenges in CMC oligonucleotide development. There is no recent precedence of global oligonucleotide marketing applications and as such it is difficult to ascertain what may and may not be acceptable. Close engagement with the regulators is something which helps to form strategies and controls and hopefully this will increase the likelihood of success of regulatory approvals going forwards.


2. How have advancements in technology improved the analytical process? Can you provide examples?

Since the last successful oligonucleotide marketing application there have been considerable enhancements in technologies. UHPLC is now common throughout the industry and techniques such as high resolution NMR and mass spectrometry are much more affordable and quick. These advances in technology mean that the resolution and robustness of methodologies can be much improved, however has a downside that the regulators may well expect us to present them with these improvements by first intent.

Increased understanding of non "typical" molecules throughout the industry has enabled wider thinking and collaboration between different pharmaceutical companies, with more people working together on the problem progress will inevitably come quicker. As more people engage with the concept of oligos and as technology continues to evolve, I anticipate a large shift in the way we look to control oligonucleotides analytically in coming years.


3. What are the most common mistakes that oligonucleotide drug developers encounter during CMC submissions?

Again, due to there being so few oligonucleotides which have gone through the full CMC process I think it is difficult to make too many sweeping statements, however the key issues that I have come across all stem from attempting to fit oligonucleotides into a box. Whether it is the small molecule group or the biopharmaceutical groups who take on the challenge of oligonucleotides, it is generally only a few "experts" within that team who work on the molecules. It is impossible to fit existing small or large molecule platforms onto oligonucleotides and a lot of time, resources and money can be wasted trying to do so! Due to the small pool of people working on the oligo projects it can also be challenging when it comes to elements such as wider reviews of submissions as the reviewers are not always as well informed about the challenges associated with oligonucleotide analysis. Education of these reviewers and key stakeholders is an activity that cannot be underestimated in time or importance! This emphasizes the benefits of cross-pharmaceutical company collaborations.


Want to hear more from industry experts like Rachel? See our exclusive TIDES speaker Q&A series here.




Share this article with your social network, just click below to share now!


Thursday, March 24, 2016

Accelerate Your Peptide from Discovery to Commercialization


Accelerate your peptide product from early discovery through late-stage development and commercialization by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

TIDES offers two tracks dedicated for peptide scientists to learn about the latest strategies and technologies needed to overcome challenges in targeting, drug discovery and peptide design, process development, regulatory, scale-up manufacturing, investment landscape and more:

Keynote Speaker:
Richard DiMarchi, Standiford H. Cox Professor of Chemistry, Indiana University
Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors

Track 1: Peptide Chemistry, Manufacturing & Controls
Speaking Organizations Include: Lonza, Bachem, Teva, Novartis, Peptron

Track 2: Peptide Discovery, Preclinical and Clinical
Speaking Organizations Include: Corden, Galena, Neon, Celerion, Phylogica

Learn about the Therapeutic Landscape of Peptides in 2016 and Beyond:
Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group
Redefining the Therapeutic Peptide Business in the 21st Century

Plus, TIDES offers the largest and most focused exhibit hall for the peptide industry, where you can access 70+ vendor booths, 40+ posters and evening cocktail networking receptions to help grow your business. You won't want to miss out on this rare opportunity to connect with 800+ like-minded researchers from across the world.

As a reader of our blog, you are eligible to save $300 when registering for TIDES - Simply use the code B16180BLOG100. Click here to register.  


Share this article with your social network, just click below to share now!


Tuesday, October 27, 2015

How to get that market authorization when the new drug is made of living cells



By Fabio D'Agostino 

Historically human cells have only been considered as the microscopic building blocks of human body and it was not until the late 1950s that Dr. E. Donnall Thomas demonstrated that bone marrow can be used to cure patients dying from blood cancers. Since then, researchers turned to cells (and stem cells) as the active pharmaceutical ingredient of the future. 

In Europe, cell-based products in which cells have been either substantially manipulated or are not intended to be used for the same essential function(s) in the recipient and the donor are regulated as medicinal products under the legal framework of Advanced Therapy Medicinal Products (ATMPs). As ATMPs developers tried to comply with the same regulatory principles as for other medicinal products, EMA recognized the need for some flexibility given the complex nature of this advanced biologics. Although a certain degree of risk-based approach might have been adopted by developers in the last 20 years, EMA formally introduced a guideline in 2013 [1].

 It is no longer the regulator but rather the developer who sets the extent of quality, nonclinical and clinical data which are necessary to submit the Market Authorization Application, given the risk profile generated for that product. Therefore, it can also be used as a strategy to justify any deviation from the technical requirements as defined in Directive 2009/120/EC. This approach was successfully applied for Holoclar®(Holostem Advanced Therapies, Italy), the first stem cell product which was granted a Marketing Authorization in the European Union in April 2015 [2]. 

Holoclar® is a transparent circular sheet of 300,000 to 1,200,000 viable autologous human corneal epithelial cells attached on a 2.2 cm diameter fibrin support in physiological transport medium. Although the manufacturer will have to provide additional post-marketing efficacy and safety data in order to confirm that the benefit-risk balance is positive, this MA represents an important landmark for developers of ATMPs. Other companies might follow in the next 12 months, such as GSK (who filed a MAA in May 2015 for their gene therapy drug - GSK2696273), Tigenix and Kiadis. It turns out that risk profile and risk mitigation are not actually just for investors but also for regulatory body and as for investors, they can tolerate risks as long as it is kept under control and a well-thought through mitigation plan is in place. 

But where do the risks lie for ATMP developers? Here are some:

1)      Quality of donor cells used as starting materials. These could be affected by high inter-donor variability and could potentially introduce tumorigenic or genetically altered cells into the product when sourcing the starting materials from patients concomitantly treated with other drugs.

2)      Quality of raw materials. As many of the raw/ancillary materials currently available are not covered by pharmacopeia’s, developers should define the quality of raw materials they need for their products (more info can be found on PAS 157, USP Ancillary materials and EP chapter on Raw Materials for ATMPs [3],[4],[5])

3)      Impossible to remove/inactivate adventitious agents once in the product. Aseptic processing and rigorous control of donor cells used as starting material are paramount.

4)      Limited stability (unless frozen) and limited amount of material available. For autologous products, this might limit the possibility for comprehensive batch release testing of the finish product (sterility, purity, identity, potency). Extensive process characterization, process validation and in process control data could supplement final product testing. 

5)      Paucity of relevant certified reference materials and the need to develop these in-house to ensure measurement reliability.

6)      Increased cell manipulations can lead to genetic modifications and/or immunogenic response (also for autologous products)

The key word is product characterization. While regulatory authorities appreciate the technical and scientific differences between characterization of cell based drugs and other medicinal products, it is paramount to characterize the product in order to identify and confirm which quality attributes (QA) are critical to quality (CQA). This is also necessary to identify and confirm the critical process parameters (process characterization). 

Arguably, two of the most discussed issues with product characterization are purity and potency. The former has to take into consideration the cells intended to elicit the therapeutic effect, all the other cells present into the products and also the remainders of cell debris, exosomes and reagents which might be present. For Holoclar®, the marketing authorization holder on the basis of clinical data justified that the active substance consists of a mixture of cells with an average of 3.5% of limbal stem cells as the main functional component. These were histochemically quantified by expression of the phenotypic marker p63-bright. Clonogenic transienty amplifying cells and terminally differentiated corneal epithelial cells are also present in the final product but these were not regarded as impurities but as supportive cell populations for the formation of the epithelial circular sheet structure. This is an example of cell-based product where purification steps are not necessary as both the active substance and supportive cell population act in concert to deliver the therapeutic effect.  Even more complicated is perhaps the development of a potency assay which should be validated before entering pivotal clinical trials.

Suggested approach is to define a number of biological assays that can be correlated with clinical outcome as more data become available. It should be then possible to identify one or more markers which correlate with the biological function of the product (i.e. their mechanism of action), like the minimum amount of p63-bright cells for Holoclar®. 

More examples can be found in Bravery at al.’s paper [6]. Perhaps 20 or 30 years from now, we will be able to handle human cells like they were chemically defined entity and regulatory authorities will have issued “the magic to do list” to get an ATMP approved. Sadly, this is quite far from today’s reality. This should not mean that patients have to wait that long to get access to these therapies.

Fabio D’Agostino is a passionate life sciences professional with experience in both the medical device and biopharmaceutical industry. An active member of the PDA Cell and Gene Task Force, he has contributed to a number of conferences in the cell and gene therapy industries. He was also instrumental in the launch of the new journal: Cell and Gene Therapy Insights.
After graduating with Honours from the Polytechnic University of Turin (Italy) with a BSc and a Master’s in Biomedical Engineering, he started his career at LivaNova (formerly Sorin Group) before moving to Newcastle University to take an Engineering Doctorate in Biopharmaceutical Process Development. He currently holds a research position at the Institute of Genetic Medicine (Newcastle University) where he is responsible for the development of an innovative platform for modular tissue engineering.

References
[1] EMA/CAT/CPWP Guideline on the risk-based approach according to annex I, part IV of Directive  2001/83/EC applied to Advanced therapy medicinal products (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139748.pdf )

[2] Flory E, Gasparini P, Jekerle V et al. Regulatory viewpoints on the development of advanced stem cell-based medicinal products in light of the first EU-approved stem cell product. Cell Gene Therapy Insights 1(1), 109-127 (2015) www.dx.doi.org/10.18609/cgti.2015.010

 
 
[5] http://pharmeuropa.edqm.eu/PharmeuropaArchives/ (EP general chapter 5.2.12)

[6]          Bravery, C. a., Carmen, J., Fong, T., Oprea, W., Hoogendoorn, K. H., Woda, J., … Van’T Hof, W. (2013). Potency assay development for cellular therapy products: An ISCT* review of the requirements and experiences in the industry. Cytotherapy, 15(1), 9–19. http://doi.org/10.1016/j.jcyt.2012.10.008


Share this article with your social network, just click below to share now!


Friday, October 16, 2015

Exclusive Interview with Anthony Rees from University of Bath

Anthony Rees, MA, DPhil, DSc, Principal, Rees Consulting AB and Emeritus Professor, University of Bath sat down at Antibody Engineering & Therapeutics after his keynote session "The Antibody Molecule: A Journey through Time" to discuss the topic further with this exclusive Q&A.




You can access the complete keynote session from Anthony Rees by clicking here.


The Antibody Engineering & Therapeutics conference is scheduled for December 7-10, 2015 in San Diego.

Want to learn more? Download the brochure or register now.


Share this article with your social network, just click below to share now!


Thursday, September 24, 2015

Exclusive Interview with Dr. Ian Tomlinson of GlaxoSmithKline

As Senior Vice President and Head of Biopharmaceuticals R&D and Head of Biopharmaceuticals R&D and Worldwide Business Development (WWBD) at GlaxoSmithKline, Dr. Tomlinson combines the resources and development expertise of a large pharmaceutical company, with the entrepreneurial spirit of a smaller biotech organization, bringing early research, late-stage biopharm development and manufacturing expertise into one organization. He served as the Chief Scientific Officer and Executive Vice President of Domantis Inc., and Domantis Limited. Dr. Tomlinson co-founded Domantis Limited in 2000.

In this interview, listen to his views on antibody therapeutic development, shaped by his background both in large pharma and smaller biotech.


Ian Tomlinson is one of the scientific advisory board members and organizers of the Antibody Engineering & Therapeutics conference scheduled for December 7-10, 2015 in San Diego.

Download the event agenda now.

Register now with the code D15172BLOG and save $400!


Share this article with your social network, just click below to share now!


Friday, September 11, 2015

Interview with Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland

The Laboratory of Andreas Plückthun studies the creation of new proteins and protein variants. The purpose of this work is to use such engineered proteins to enable research and applications which have been very difficult or even impossible so far. Example endeavors in his lab include the creation of new engineered binding proteins to inhibit other proteins or to kill tumor cells, or the stabilization of proteins so that they can be studied structurally and biophysically.

Watch this interview in which Andreas shares his views on antibody research and exciting developments in his lab.


Andreas Plückthun is one of the scientific advisory board members and organizers of the Antibody Engineering & Therapeutics conference scheduled for December 7-10, 2015 in San Diego. He will also be chairing a session at the event on “New Aspects of Prodrug Targeting” and giving a presentation at the event titled “Protein Engineering Approaches to Protein Toxic Prodrugs”

Want to learn more? Download the brochure or register now. 


Share this article with your social network, just click below to share now!


Thursday, September 3, 2015

Labor Day Weekend Sale! Save 30% off IBC’s Antibody Engineering & Therapeutics event


Take advantage of this special Labor Day Weekend offer and save 30% to Antibody Engineering & Therapeutics! Register with code AE201530 to activate your 30% discount off the standard rates to IBC’s 26th Annual Antibody Engineering & Therapeutics event taking place December 7-10, 2015 in San Diego, CA. Visit the website for full event details.

This limited-time offer expires on Monday, September 7th | Register here.

Now in its 26th year, IBC's Antibody Engineering & Therapeutics is the largest and most trusted antibody engineering and therapeutics event in the industry. As the leader in this space, we’ve continued to provide an impressive collection of world-renowned and highly-published academic and industry scientists, who share the latest science, strategies and preclinical/clinical development efforts. Connect with 700+ experts to discover, engineer and develop novel and next-generation antibody modalitites across diverse disease indications.

Activate your 30% savings now with code AE201530! Offer expires 9/7

Qualifications, rules and regulations: 
Offer cannot be applied retroactively to confirmed or pending registrations from today's date and prior. 30% discount cannot be combined with any team discounts or other promotions and/or discount offers. Discount is only valid from September 3rd – September 7th, 2015. All registrations are subject to IIR/IBC approval. Discount cannot be applied to the Academic/Government Rates.


Share this article with your social network, just click below to share now!


Monday, July 27, 2015

What did last year's Antibody Engineering & Therapeutics attendees have to say about their experience?

See what attendees of last year's Antibody Engineering & Therapeutics had to say...

"Comprehensive coverage. In-depth analyses of the past, present and outlook of the antibody therapyfield/industry" - Li-Hsien Wang, Regeneron


"I am new in the antibody therapeutic field and this conference provides significant amounts of valuable information to me." - Ulrik Lademann, Senior Scientist, Symphogen

"This is best meeting dedicated to Antibodies! Small enough to be able to be able to interact with people and big enough to cover all the important topics" - Monica Schaller, University Hospital Bern Inselspit

"Great conference, inspiring atmosphere, very motivating speakers and encouraging networking sessions!! Would love to come back!" - Priyal Thakur, BD Biosciences

"Great conference! Informative and addresses state-of-the-art advances in antibody/drug technologies." - James Tamura, Macrogenics

"Beautiful overview on antibody modeling strategies of different players on the market!" - Tobias Raum, Amgen Research Munich

"The most updated conference on Antibody Engineering & Therapeutics" - Jean-Luc Teillaud, INSERM, France

"The workshop program continues to be a venue for in-depth exploration of specialty topics on antibodies" - Ray Sweet, Senior Director and Fellow, Biologics Research, Janssen R&D

"Informative and Timely!" - Colin Brenan, CTO, R&D, HiFiBio BV

"World class group of leading antibody researchers" - Caroll Osgood, Alleghany Brain and Spine


Don't miss out on the #1 forum for academia and industry to connect for scientific exchange and networking in antibody engineering & therapeutics, immunobiology and next-generation binders.

Check out the complete program here.

Register today with the code D15172BLOG and save $550!


Share this article with your social network, just click below to share now!


Thursday, July 23, 2015

Antibody Engineering & Therapeutics Interview | Paul Sondel, M.D. Ph.D., University of Wisconsin

The annual Antibody Engineering & Therapeutics is the #1 forum for academia and industry to connect for scientific exchange and networking in antibody engineering & therapeutics, immunobiology and next-generation binders. The 2015 event is taking place December 7-10 in San Diego, CA.

Below is an interview conducted at the 2014 event with Paul Sondel, M.D. Ph.D., Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, University of Wisconsin. At the event, Dr. Sondel presented "Translating Preclinical Immunocytokine Development into Clinical Testing"

Check out his interview below...



Want to hear more from experts like Dr. Sondel? Then join us at the 2015 Antibody Engineering & Therapeutics event. Register today at save $550 when you use the code D15172BLOG.

See you in San Diego!



Share this article with your social network, just click below to share now!


Wednesday, July 15, 2015

Highlights from the 2014 Antibody Engineering & Therapeutics Conference


The annual Antibody Engineering & Therapeutics is the #1 forum for academia and industry to connect for scientific exchange and networking in antibody engineering & therapeutics, immunobiology and next-generation binders.  The 2015 event is taking place December 7-10 in San Diego, CA. Below are highlights from the 2014 event...




Interested in attending the 2015 event? Register today and save $550 when you use the code D15172BLOG


Share this article with your social network, just click below to share now!


Thursday, July 9, 2015

The Antibody Engineering & Therapeutics Final Agenda is Now Available












The Antibody Engineering & Therapeutics Final Agenda is Now Available! Click Here to Download Your Copy >>

At the upcoming IBC's 26th Annual Antibody Engineering & Therapeutics meeting in San Diego, CA on December 7-10, 2015, connect with 700+ of your peers and industry experts to discover, engineer and develop novel and next-generation antibody modalities across diverse disease indications.

This year's program includes an impressive collection of world-renowned and highly-published academic and industry scientists, who will be sharing the latest science, strategies and preclinical/clinical development efforts.

Download the brochure today to see how you can fast-tract your antibody research to the clinic and beyond at the most trusted antibody engineering and therapeutics event of the year!

Learn About The Latest Antibody Science and Applications:
• 64 unpublished and new data presentations from trusted industry and academic scientists
• 100+ research projects presented live in the Poster Hall with one-on-one access to the researchers
• 16+ Scientific Briefings to help you apply novel technologies

Expand Your Pipeline of Antibody Therapeutics: 
• Find and exploit new antibody targets beyond the “low-hanging fruit”
• Overcome the challenges of complex molecules like bispecifics, fusions, ADCs, antibody combinations to gain a competitive advantage
• Assess lessons learned from numerous preclinical and clinical projects to accelerate your molecules

PLUS! We're excited to announce the ALL-NEW Antibody-Drug Conjugate (ADC) Development track, covering: 
• Novel conjugation approaches
• Novel linkers and payloads
• Preclinical and clinical results
• New ADC targets • Strategies to maximize potency
• Widening therapeutic window
• Improving process development and analytics for ADCs

Register today to take advantage of the early-bird savings of up to $450 – Plus take an EXTRA $100 off with the code D15172BLOG | Click here to register.


Share this article with your social network, just click below to share now!


Thursday, July 2, 2015

Celebrate July 4th with 30% Off Select IBC Events!


Take advantage of this special July 4th offer and save 30% off the standard rates to IBC’s Cell Therapy, Bioprocessing & Commercialization, Immuno-Oncology, BioProcess International and Antibody Engineering & Therapeutics when you register by Monday, July 6th.

Cell Therapy, Bioprocessing & Commercialization - Save 30% by using the code XFLASH30 when you register. Visit the event website | Register

Immuno-Oncology - Save 30% by using the code XFLASH30 when you register. Visit the event website | Register

BioProcess International Conference & Exposition - Save 30% by using the code BPIJULY4 when you register.Visit the event website | Register

Antibody Engineering & Therapeutics - Save 30% by using the code AE201530 when you register.Visit the event website | Register


Qualifications, rules and regulations: 
Offer cannot be applied retroactively to confirmed or pending registrations from today's date and prior. 30% discount cannot be combined with any team discounts or other promotions and/or discount offers. Discount is only valid from July 2– July 6, 2015. All registrations are subject to IBC approval. Discount cannot be applied to the Academic/Government Rates.


Share this article with your social network, just click below to share now!


Monday, June 22, 2015

Antibody Engineering & Therapeutics Preliminary Agenda is Now Available


Preliminary Agenda is Now Available for Download!
 
IBC's 26th Annual Antibody Engineering & Therapeutics meeting is returning to San Diego, CA on December 7-10, 2015. Accelerate your antibody research, discovery efforts and clinical programs at the most comprehensive event for comparing and contrasting engineering, discovery and development strategies for different antibody modalities.

We’re so excited about how this year’s program is shaping up that we wanted to rush you the preliminary agenda so that you have enough information to take advantage of the early registration discount of up to $650 when you register by Friday, June 26. PLUS! Save an extra $100 with the code D15172BLOG | Total savings of $750! Register here.

This year's program includes an impressive collection of world-renowned and highly-published academic and industry scientists, who will be sharing the latest science, strategies and preclinical/clinical development efforts covering these areas:

• Bipecific antibodies: new technologies and applications
• Antibody effector functions
• Getting to reproducibility in research and diagnostic antibodies
• Antibodies to harness the cellular immune system
• Antibody targets: target, target, target...it's all about the target
• Immunotherapeutic antibody mechanisms
• Antibodies for orphan indications
• Computational antibody design
• Antibody therapeutics for non-cancer indications
• Clinical advances in antibody targeted therapeutics
• New concepts for prodrugs
• And More!

Don't miss out! Register today to take advantage of the early-bird savings of up to $750. This is the lowest rate of the year and expires on Friday, June 26th!

Click Here to Register Now >>

Be Sure to Use Code: D15172BLOG

See you in San Diego!


Share this article with your social network, just click below to share now!


Thursday, August 21, 2014

Rapid Development and Scale-Up Through Strategic Partnership: Case Study of an Integrated Approach to Cell-Line and Process Development for Therapeutic Antibodies

Today, we feature an article from our partners at BioProcess International Magazine. This is an excerpt from the article Rapid Development and Scale-Up Through Strategic Partnership: Case Study of an Integrated Approach to Cell-Line and Process Development for Therapeutic Antibodies.



WWW.COOKPHARMICA.COMOver the past decade, monoclonal antibodies have become mainstream therapeutics for treating a broad range of conditions from autoimmune disorders to cancer. Part of this evolution is increasing time and cost pressure on biopharmaceutical companies to bring new drugs to market. Additionally, companies now routinely engineer and screen molecules for developability and manufacturability during discovery before selecting a final candidate molecule.

The biosimilar development paradigm also demands significantly more bioanalytical analysis during initial cell-line and process development. Thus, a significant investment is being made to assure that molecules entering the pipeline are successful. It is therefore imperative to take an integrated approach to cell-line development and early stage screening and process development. This enables companies to make appropriate, timely decisions about pursuing therapeutic candidates for preclinical and clinical manufacturing.

A critical part of biopharmaceutical development is choosing the right cell line with the objective of confirming cell productivities, cell-line stability, and final-product quality. For a proof-of-concept program outlined herein, Cook Pharmica and Selexis were able to successfully develop a productive cell line, design an efficient process, and scale up a commercially available antibody. Selexis generated the high performance SURE CHO-M cell line that was used in Cook’s rapidly scalable development process at its state-of-the-art CGMP biologics manufacturing facility in Bloomington, IN. Current data from the program demonstrate comparability to the originator drug while achieving commercial-ready titers up to 4 g/L.

Read the full article here.



You can find out more about topics like this and meet and network with other professionals in the bioprocessing field at this year's BioProcess International Conference and Exhibition.  As a reader of this blog, when you register to join us October 20-23 in Boston, you are eligible to receive 20% off the standard rate when you mention code BPI14BLOG.



Share this article with your social network, just click below to share now!


Tuesday, June 17, 2014

See What's "Long Overdue" in the Field of Cell Therapy

In cell therapy, the Target Product Profile (TPP) is the preferred document used to record the aspirational attributes of a therapeutic.  Anthony Davies, Ph.D., President of Dark Horse Consulting, is a leading expert on TTPs and will be presenting on the specifics of authoring a TPP at this year’s Cell Therapy and Bioprocessing Conference.  He was able to shed some light for us on the current state of TTPs in the field:  

Are Target Product Profiles being increasingly adopted as development and as a mode of regulatory communications?

Anthony: Yes, they are and this is also long overdue. The TPP was introduced by the FDA quite some time ago as a way of capturing your expiration or profile of your product. It is, at last, being adopted more widely by industry. This is much appreciated by the regulatory agencies. It is a very good tool for two purposes.

First of all, from the first interaction the product ever has with a regulatory agency, this enabled the agency to frame the complete trajectory of product development all the way through to commercialization and gives them a tremendous perspective on what they are trying to do in developing these drugs. It’s repeated provision for the agency as the drug moves out of development product and keeps everything on track and keeps everybody realistic about where the drug is meant to be at each stage of development.

Cell Therapy Target Product ProfilesInterestingly, it’s also being adopted by biotech companies and pharmaceutical companies as an internal method of tracking the progression of the drug development. The use in both the external, regulatory view of the drug and the internal corporate view of the drug development is a really nice harmonizing tool. I’m very happy at the Conference to be giving a presentation on the nitty gritty of how to fill out a TTP for cell therapy. I hope it will be very useful for the attendees.

Anthony’s full interview can be found in this year’s brochure.  

You can hear more from Anthony and other leaders in the space at this year’s Cell Therapy Bioprocessing Conference.  Join us September 15-16 in Arlington, VA.  Save $100 as a reader of this blog when you register to join us and mention code XB14189BLOG.

Sign up for email updates
Check us out on LinkedIn
Follow us on Twitter
Like us on Facebook


Share this article with your social network, just click below to share now!